Abstract

The Contractor shall provide for nearly all the operations and technical support necessary to the entire NCI Frederick Cancer Research Facility (FCRF), both for the four collocated Contractors (approximately 1,400 FTEs) and the Government (approximately 325 FTEs), as well as the maintenance and upkeep of the FCRF buildings and grounds. Such support shall include, but not be limited to: a. Business and administrative management; b. Facilities maintenance and construction; c. Support of NIH/NCI intramural research programs; d. Fermentation production (large scale); e. Environmental control and safety research; f. Occupational health care; g. Research services support; h. Animal health diagnostic service and quarantine; i. Animal holding/technical support; j. Supercomputer services; and k. Shared services.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Office of The Director, NCI (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CO074102-094
Application #
2304314
Study Section
Project Start
1987-09-26
Project End
1997-03-25
Budget Start
1996-06-27
Budget End
1997-03-25
Support Year
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Program Resources, Inc.
Department
Type
DUNS #
City
Reston
State
VA
Country
United States
Zip Code

  Publications

Asojo, Oluwatoyin A; Gulnik, Sergei V; Afonina, Elena et al. (2003) Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J Mol Biol 327:173-81
Asojo, Oluwatoyin A; Afonina, Elena; Gulnik, Sergei V et al. (2002) Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370. Acta Crystallogr D Biol Crystallogr 58:2001-8
Lunn, G; Phillips, L R; Pacula-Cox, C (1998) Reversed-phase high-performance liquid chromatography of 4-(2-pyridyl)-1-piperazinethiocarboxylic acid 2-[1-(pyridyl)ethylidene]hydrazide dihydrochloride (NSC 348977), a synthetic thiosemicarbazone with antitumor activity. J Chromatogr B Biomed Sci Appl 708:217-22
Mehta, R R; Graves, J M; Shilkaitis, A et al. (1998) Development of a new metastatic human breast carcinoma xenograft line. Br J Cancer 77:595-604
Silva, A M; Lee, A Y; Erickson, J W et al. (1998) Structural analysis of plasmepsin II. A comparison with human aspartic proteases. Adv Exp Med Biol 436:363-73
Mehta, R R; Hawthorne, M E; Graves, J M et al. (1998) Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur J Cancer 34:902-7
Shiao, Y H; Buzard, G S; Weghorst, C M et al. (1997) DNA template as a source of artifact in the detection of p53 gene mutations using archived tissue. Biotechniques 22:608-10, 612
Chertov, O; Michiel, D F; Xu, L et al. (1996) Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 271:2935-40
Curti, B D; Ochoa, A C; Urba, W J et al. (1996) Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients. J Immunother Emphasis Tumor Immunol 19:296-308
Siders, W M; Halloran, P J; Fenton, R G (1996) Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res 56:5638-46

Showing the most recent 10 out of 567 publications